Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917453 | 0.87 | CA2 (0.46) | CA2ANPEPADH1BADH1CADH1A | |
| SCHEMBL7919805 | 0.85 | CA2 (0.45) | CA2ANPEPADH1BADH1CADH1A | |
| SCHEMBL11147726 | 0.84 | KMT2A (0.34) | CYP2C19CYP2D6PTGS1PDE4ALMNA | |
| SCHEMBL11797629 | 0.84 | CA2 (0.41) | CA2ANPEPADH1BADH1CADH1A | |
| SCHEMBL28038412 | 0.83 | KMT2A (0.33) | CYP2C19CYP2D6PTGS1PDE4ALMNA | |
| SCHEMBL1553508 | 0.83 | PTGS1 (0.36) | CA2ANPEPCYP2C19CYP2D6PTGS1 | |
| SCHEMBL11570601 | 0.82 | KDM4E (0.31) | CA2LMNABLM | |
| SCHEMBL19523471 | 0.81 | CYP2D6 (0.41) | CA12CA7CA9CA14CYP2C19 | |
| SCHEMBL14100075 | 0.80 | POLB (0.33) | ANPEPCYP2C19CYP2D6PTGS1PDE4A | |
| SCHEMBL12541389 | 0.79 | APAF1 (0.36) | CYP2C19CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10710986-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190270727-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-09-05 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-7414076-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-08-19 | — | — | US | disclosed |
| US-7414076-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-08-19 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-5434276-A | Process for making N-acyl taurides | FINETEX, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995018095-A1 | PROCESS FOR MAKING N-ACYL TAURIDES | FINETEX, INC. (US) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CA2 3474/4885ANPEP 3345/4885ADH1B 717/4885 |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CA2 3474/4885ANPEP 3345/4885ADH1B 717/4885 |
| US-10710986-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | CA2 3474/4885ANPEP 3345/4885ADH1B 717/4885 |
| US-20190270727-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | CA2 3474/4885ANPEP 3345/4885ADH1B 717/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | CA2 2487/4885ANPEP 164/4885ADH1B 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.